Benefits and Applications of Oncotype DX Breast Recurrence Score Testing among Breast Cancer Patients: Current Recommendations and Controversies.
Oncotype DX Breast Recurrence Score is a prognostic and predictive assay of 21 genes, initially designed for therapy planning in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, lymph node-negative or lymph node-positive (maximum 3 nodes involve...
Saved in:
| Main Authors: | Elena-Diana Chiru, Marcus Vetter |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2023-06-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2023.16.107 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Radiomics Analysis of Breast MRI to Predict Oncotype Dx Recurrence Score: Systematic Review
by: Nathan Kim, et al.
Published: (2025-04-01) -
Probability of a high recurrence score for breast cancer on the Oncotype DX test in males: a case series
by: Rafael Everton Assunção Ribeiro da Costa, et al.
Published: (2023-10-01) -
Nomogram Development for Assessing Oncotype DX Recurrence Scores in Breast Cancer: A Chinese Population Study
by: Jiayin Song, et al.
Published: (2025-03-01) -
Commentary on oncotype Dx
by: Prashant Mehta, et al.
Published: (2019-01-01) -
Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands
by: Felix E. de Jongh, et al.
Published: (2022-01-01)